Gilead Sciences Inc (NASDAQ:GILD)

70.06
Delayed Data
As of 4:37pm ET
 +1.14 / +1.65%
Today’s Change
56.56
Today|||52-Week Range
75.04
+20.25%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$86.6B

Company Description

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Contact Information

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City California 94404
P:(650) 574-3000
Investor Relations:
(650) 358-1054

Employees

Shareholders

Mutual fund holders51.01%
Other institutional29.32%
Individual stakeholders1.27%

Top Executives

Daniel P. O'DayChairman & Chief Executive Officer
Andrew D. DickinsonChief Financial Officer
Merdad V. ParseyChief Medical Officer
Flavius MartinExecutive Vice President-Research
Brett A. PletcherSecretary, Chief Compliance Officer & Executive VP